<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658512</url>
  </required_header>
  <id_info>
    <org_study_id>247/2017BO1</org_study_id>
    <nct_id>NCT03658512</nct_id>
  </id_info>
  <brief_title>Tübinger Diabetes Mellitus Database (TUEDID)</brief_title>
  <official_title>Tübinger Diabetes Mellitus Database (TUEDID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus is a widespread disease with increasing prevalence worldwide. Patients with
      diabetes can develop multiple late complications such as neuropathy, retinopathy, nephropathy
      and cardiovascular comorbidities. So far, there are no reliable predictive tools or markers
      to estimate if, when and to what extent a patient with diabetes develops late complications.
      For the patients quality of life and for health economic reasons an improved risk assessment
      would be desirable. The prospective TUEDID study will characterize diabetic patients to look
      out for parameters the predict progression of diabetes and its complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control (blood glucose)</measure>
    <time_frame>At enrolment</time_frame>
    <description>Assessed as fasting blood glucose and HbA1C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic control (HbA1C)</measure>
    <time_frame>At enrolment</time_frame>
    <description>Assessed as fasting HbA1C</description>
  </primary_outcome>
  <other_outcome>
    <measure>Liver function</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for liver function will be assessed (GOT, GPT, AP, Gamma-GT, Lipase, all [U/l])</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for renal function will be assessed (Creatinine, Urea, Cystatin C, all [mg/dl])</description>
  </other_outcome>
  <other_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>At enrolment</time_frame>
    <description>Glomerular filtration rate will be determined [ml/min/1,73 m²]</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid status</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for evaluation of lipid status will be assessed (LDL, HDL, Cholesterol, triglycerides, all [mg/dl])</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters to evaluate the inflammatory state will be assessed (CRP [mg/dl])</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulinemia</measure>
    <time_frame>At enrolment</time_frame>
    <description>Insulin and C-peptide concentrations will be assessed [pmol/l]</description>
  </other_outcome>
  <other_outcome>
    <measure>Hormones</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for evaluation of hormonal status will be assessed (TSH [mU/l])</description>
  </other_outcome>
  <other_outcome>
    <measure>Hormones</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for evaluation of hormonal status will be assessed (fT3 and fT4 [pmol/l])</description>
  </other_outcome>
  <other_outcome>
    <measure>Hormones</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for evaluation of hormonal status will be assessed (Cortisol [nmol/l])</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine parameters</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters from urine will be assessed (albumin, total protein, both [mg/l])</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine parameters</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters from urine will be assessed (creatinine [ml/min])</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine parameters</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters from urine will be assessed (urine sediment via microscopy)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pancreas</measure>
    <time_frame>At enrolment</time_frame>
    <description>Lipase and amlyase concentrations for evaluation of pancreas status will be assessed [U/l]</description>
  </other_outcome>
  <other_outcome>
    <measure>Coagulation</measure>
    <time_frame>At enrolment</time_frame>
    <description>Parameters for evaluation of coagulation status will be assessed (INR, blood cell count)</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiological examination</measure>
    <time_frame>At enrolment</time_frame>
    <description>Angiological examination of parameters for vascular function</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of height and weight</measure>
    <time_frame>At enrolment</time_frame>
    <description>Height and weight will be measured and reported as BMI (kg/m^2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of waist and hip circumference</measure>
    <time_frame>At enrolment</time_frame>
    <description>Waist and hip circumference will be measured and reported as waist-to-hip ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>At enrolment</time_frame>
    <description>Blood pressure will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>At enrolment</time_frame>
    <description>Heart rate will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of advanced glycation endproducts</measure>
    <time_frame>At enrolment</time_frame>
    <description>Will be assessed by AGE reader</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>At enrolment</time_frame>
    <description>Body fat content and lean mass will be assessed by bioimpedance analysis</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TUEDID cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        People with or without diabetes who are treated at the University Hospital Tübingen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years

        Exclusion Criteria:

          -  no written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29 80687</phone>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tuebingen, Internal medicine IV</name>
      <address>
        <city>Tuebingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Fritsch, Prof, MD</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>82711</phone_ext>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Fritsche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

